The catalytic domains of the Raf family of protein kinases (DRaf) dier in their ability to activate MEK in vitro and in vivo and in their ability to oncogenically transform mammalian cells. The kinase domain of B-Raf is more active than the equivalent portion of Raf-1 which in turn is more active than A-Raf. In Raf-1 the phosphorylation or mutation to aspartic acid of two key tyrosine residues upstream of the ATP binding site has been demonstrated to signi®cantly potentiate catalytic activity. In A-Raf the analogous amino acids are also tyrosine whereas in B-Raf they are aspartic acid. To determine if these dierences in amino acid sequence in¯uence the relative catalytic activity of the Raf kinase domains we constructed forms of DA-Raf, DB-Raf and DRaf-1 that encode either aspartic acid forms of the DRaf-1:ER and DA-Raf:ER proteins were the most potently oncogenic which correlated with their ability to elicit activation of the MAP kinase pathway. Consistent with the transformation data, the catalytic activity of the [DD] forms of DA-Raf:ER and DRaf-1:ER was about ten times greater than the cognate [FF] and [YY] forms of the proteins. By contrast all of the DB-Raf:ER proteins were highly transforming and DBRaf catalytic activity was largely unaected by mutation of the aforementioned aspartic acids to either tyrosine or phenylalanine. Similar results were obtained with epitope-tagged forms of DA-Raf, DB-Raf and DRaf-1 expressed in Sf9 cells. These data provide support for the model that key tyrosine residues in the protein kinase domains of A-Raf and Raf-1 are important in the regulation of catalytic activity. In addition they demonstrate that the higher intrinsic activity of B-Raf cannot be explained simply by the presence of aspartic acids at the analogous positions.
Introduction
The Raf family of protein kinases play a pivotal role in the control of cell proliferation and dierentiation by relaying signals from activated cell surface receptors via MEK and MAP kinase to a variety of intracellular eectors (Morrison, 1990; Rapp, 1991; Storm et al., 1990) . In mammals, there are three members of the Raf protein kinase family: Raf-1, A-Raf and B-Raf. All three Raf proteins are composed of a conserved aminoterminal regulatory region and a carboxy-terminal protein kinase domain. The regulatory domains of Raf proteins are composed of two conserved regions (CR1 and CR2), with the protein kinase domain (CR3) located in the carboxy-terminal half of the protein. The CR1 region encodes the Ras binding domain of the protein and a`cysteine ®nger' Finney et al., 1993; Koide et al., 1993; Moodie et al., 1993; Papin et al., 1996; Van Aelst et al., 1993; Vojtek et al., 1993; Warne et al., 1993; Zhang et al., 1993) . Although CR1 and CR2 contain regulatory sites of phosphorylation, it appears that the CR2 region is the major negative regulator of protein kinase activity as a deletion encompassing this region in Raf-1 is constitutively activated and capable of promoting oncogenic transformation of several cell types (Beck et al., 1987; Ikawa et al., 1988; Marx et al., 1988; Stanton et al., 1989) .
A plethora of polypeptide factors including epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and nerve growth factor (NGF) elicit the activation of Ras proteins into their GTP-bound state Morrison, 1990; Rapp, 1991) . Activated Ras recruits Raf-1 to the plasma membrane where it is activated by a mechanism that remains poorly de®ned. It has been reported that a variety of protein kinases including Src family kinases (Fabian et al., 1993; Marais et al., 1995) and Protein Kinase C (PKC) (Carroll and May, 1994; Kolch et al., 1993; Sozeri et al., 1992) as well as lipid co-factors (Dent et al., 1995; Ghosh et al., 1996) can potentiate Raf-1 activity. Furthermore, Raf proteins are found in complex with members of the 14-3-3 family of proteins that may both regulate activity and perhaps serve to facilitate the construction of higher order signaling complexes within the cell (Braselmann and McCormick, 1995; Freed et al., 1994; Liu et al., 1995; Papin et al., 1996; Xiao et al., 1995) . In addition, recent evidence has suggested a role for dimerization in the regulation of Raf-1 catalytic activity (Farrar et al., 1996; Luo et al, 1996) .
Once activated Raf-1 can phosphorylate and activate the dual-speci®city protein kinases MEK1 and MEK2, which in turn phosphorylate and activate the Mitogen Activated/Extracellular ligand regulated (MAP/ERK) protein kinases (Ahn et al., 1992; Ashworth et al., 1992; Avruch et al., 1994; Crews et al., 1992; Dent et al., 1992; Howe and Marshall, 1993; Kyriakis et al., kinases elicit pleiotropic eects within the cell by phosphorylating a number of proteins including other protein kinases, transcription factors (Hill et al., 1993; Marais et al., 1993; McCarthy et al., 1997) , guanine nucleotide exchange proteins (Cherniack et al., 1994; Samuels and McMahon, 1994) and phospholipase A 2 (Lin et al., 1993; Nemeno et al., 1993) . The inappropriate activation of this pathway is believed to be a key step in the process of Ras-mediated tumorigenesis in humans.
The utility of estradiol-regulated forms of oncogenic A-Raf, B-Raf and Raf-1 (DRaf:ER) in elucidating the biological and biochemical changes that lead to oncogenic transformation has been established. Activation of DRaf-1:ER in NIH3T3 cells leads to the rapid activation of MEK and MAP kinase, regulation of the expression of genes such as Heparin-Binding EGF (HB-EGF) and ultimately to oncogenic transformation (McCarthy et al., 1995 (McCarthy et al., , 1997 Pritchard et al., 1995; Samuels et al., 1993) .
We have previously identi®ed biological and biochemical dierences between the dierent DRaf:ER proteins expressed in 3T3 cells. DB-Raf:ER is the most potent activator of the MAP kinase pathway whereas DA-Raf:ER appears to be the weakest. In vitro, epitope-tagged forms of the Raf kinases expressed in Sf9 cells display dierences in catalytic activity that re¯ect their activity in 3T3 cells. DB-Raf phosphorylated and activated MEK1 approximately ten times more eciently than DRaf-1 and 500 times more eciently than DA-Raf .
Previous work has identi®ed two key tyrosine residues (Y340, Y341) in the catalytic domain of Raf-1 as being important in the regulation of protein kinase activity. Phosphorylation or mutation of these residues to aspartic acid led to constitutive activation of the catalytic activity of Raf-1. By contrast, mutation to phenylalanine had no eect on basal activity (Marais et al., 1995; Fabian et al., 1993) . Sequence alignment of the catalytic domains of all three Raf proteins revealed dierences in amino acid sequence in this region that may begin to explain the dierences observed in catalytic activity. In A-Raf the analogous amino acids are tyrosines 299 and 300 (Y299 and Y300) but in BRaf the analogous amino acids are both aspartic acid (D492 and D493) (Ikawa et al., 1988; Marx et al., 1988) . We therefore reasoned that, in a manner analogous to Raf-1, mutation of these tyrosines to aspartic acid might potentiate the activity of A-Raf whereas in B-Raf mutation of the corresponding aspartic acid residues to phenylalanine or tyrosine might abrogate catalytic activity.
In order to address these issues we have constructed forms of the catalytic domains of Raf-1, A-Raf and BRaf which encode either tyrosine, phenylalanine or aspartic acid at the aforementioned positions. We have expressed these proteins in mammalian cells as ER fusion proteins and analysed their biological and biochemical properties. In addition, we have con®rmed the biochemical analysis by expressing epitopetagged forms of the proteins in Sf9 cells. As predicted, the [DD] forms of DRaf-1 and DA-Raf display elevated catalytic activity and enhanced oncogenic potential. By contrast all of the forms of DB-Raf retain the same elevated catalytic activity and are potently oncogenic in mammalian cells. The elevated activity of B-Raf is not therefore due simply to the presence of aspartic acid residues in the aforementioned positions. These experiments further illuminate the dierences between the three mammalian Raf kinases and may provide clues as to the role of these proteins in the response of cells to dierent types of extracellular stimuli.
Results

Oncogenic transformation of cells by retroviruses encoding the dierent DRaf:ER proteins
Using standard techniques of site directed mutagenesis we constructed forms of DA-Raf, DB-Raf and DRaf-1 encoding either aspartic acid [DD] , phenylalanine [FF] or tyrosine [YY] at the sites previously identi®ed by others as being involved in the regulation of Raf-1 kinase activity (Fabian et al., 1993; Marais et al., 1995) . These forms of DRaf were engineered to be expressed either in replication-defective retrovirus vectors as fusions with the hormone binding of the estrogen receptor or as FLAG-tagged proteins in a baculovirus transfer vector as described previously and as indicated in Figure 1 . Retrovirus stocks for the infection of target cells were derived by transient transfection of Bosc23 cells (Pear et al., 1993) as described in Materials and methods.
Infection of Rat1 and 3T3 cells with retroviruses encoding each of the DRaf:ER proteins gave rise to 510 5 puromycin resistant colonies that, in the absence of hormone, displayed a¯at, non-transformed morphology similar to that of the parental cells or cells infected with a retrovirus encoding DRaf301:ER, a kinase-inactive form of DRaf-1:ER (Figure 2 , 7ICI as indicated and data not shown). This result is consistent with previous observations that, even in pooled populations, very few cells expressing DRaf-1:ER Figure 1 Schematic representation of DRaf:ER and DRaf:FH 6 constructs used in this study. Point mutations were introduced into plasmids encoding the catalytic domains of Raf-1(DRaf-1), A-Raf (DA-Raf) and B-Raf (DB-Raf) to generate the [YY] , [DD] and [FF] forms of each of the Raf protein kinases used in this study as described in Materials and methods. The relative positions of the mutated amino acids and the VAVK motif of the ATP binding site are indicated. After DNA sequence veri®cation, sequences encoding the dierent DRaf kinase domains were subcloned into pBP3:hbER, a derivative of pBabepuro that encodes the hormone binding domain of the HE14 allele of the human estrogen receptor. As indicated the expression of the DRaf:ER genes is promoted by the MLV LTR and expression of the puromycin resistance gene is promoted by the SV40 early promoter. The DRaf kinase domains were also subcloned into the baculovirus transfer vector pVL1393:FH 6 to generate forms of the proteins epitope-tagged with the FLAG epitope and 6 Histidine residues at the amino terminus display signs of morphological transformation in the absence of added hormone. Addition of ICI to Rat1 cells expressing the [YY] , [FF] or [DD] forms of DRaf-1:ER for 48 h led to the cells displaying a rounded, refractile and spindle shaped morphology which is characteristic of oncogenic transformation ( Figure 2N , P and R, respectively). DRaf-1 [DD] :ER activation elicited the most rapid and striking alterations in cell morphology. At prolonged times after DRaf-1 [DD] :ER activation we noted that cells were lost from the surface of the dish presumably because of changes in their adhesive properties or induced apoptosis ( Figure  2R Figure 2B and F, respectively) and again the [DD] form showed the most rapid alterations in cell morphology. Interestingly, the addition of ICI to Rat1 cells expressing DA-Raf [FF] :ER did not elicit any obvious manifestations of morphological transformation even after prolonged ICI treatment up to 120 h ( Figure 2D ). This result is similar to that seen when DRaf301:ER is expressed in 3T3 and Rat1 cells (data not shown).
All of the transforming DRaf:ER proteins responded to b-estradiol, 4-hydroxy-tamoxifen and ICI 182,780 as has been described previously for DRaf-1:ER (Samuels et al., 1993) whereas DA-Raf [FF] :ER showed no response to any of these hormones. We have previously extensively documented that none of the estrogen receptor agonists or antagonists used in these studies has any eect on the morphology of either parental 3T3 or Rat1 cells (Samuels et al., 1993) . All of the transforming DRaf:ER proteins elicited potent morphological transformation of Rat1 cells in the absence of fetal calf serum indicating that the maintenance of serum growth factors plays little or no role in the ability of DRaf:ER proteins to give rise to alterations in cell morphology. Similar experiments were conducted in NIH3T3 cells with similar results (data not shown).
The potential of the dierent DRaf:ER proteins to induce oncogenic transformation was con®rmed by testing the ability of Rat1 cells expressing the dierent DRaf:ER proteins to form colonies in agarose. Consistent with the morphological transformation data, all of the DRaf-1:ER and DB-Raf:ER proteins elicited hormone-dependent colony formation. Rat1 cells expressing either the [YY] or [DD] forms of DARaf:ER also formed colonies in agarose in a hormonedependent manner. However, Rat1 cells expressing DRaf [FF] :ER showed an extremely limited capacity to form colonies in agarose (data not shown).
Expression of DRaf:ER proteins in Rat1 cells
Treatment of 3T3 cells expressing DRaf:ER proteins with ICI leads to an increase in the expression of the fusion proteins over a 24 h time course. Increased DRaf:ER expression is due, at least in part, to a 2 ± 3 fold increase in DRaf:ER mRNA expression as well as a selective stabilization of the DRaf:ER proteins within the cell (Samuels et al., 1993) .
To con®rm the expression of each of the DRaf:ER proteins, cell lysates were prepared from the retrovirus infected Rat1 cells described above that had either been untreated (0) (Figure 3a) . Similar increases in expression were observed after the addition of ICI to cells expressing the dierent forms of DB-Raf:ER (Figure 3c ).
Prior to the addition of ICI, the basal level of expression of all three DA-Raf:ER proteins appeared to be slightly higher compared to the level of expression of the cognate DRaf-1:ER proteins ( Figure  3b and a, respectively). The abundance of DARaf [YY] :ER increased approximately threefold after 24 h of ICI treatment (Figure 3b as indicated). The [DD] and [FF] forms of DA-Raf:ER displayed similar kinetics of induction (Figure 3b ). These results demonstrated that the introduced point mutations did not have a severe eect on the expression of DRaf:ER proteins. Is is also evident from this experiment that the apparent inability of DA-Raf [FF] :ER to transform cells is not due to a lack of expression of the fusion protein.
Activation of the MAP kinase cascade in cells transformed by DRaf:ER proteins Activation of DRaf-1:ER in 3T3 cells leads to the rapid, protein synthesis independent activation of MEK and the p42/p44 MAP kinases (Samuels et al., 1993) . We have previously demonstrated that the catalytic domains of the three dierent Raf kinases display dierent biological and biochemical properties when expressed in cells . We wished therefore to assess whether the aforementioned differences in amino acid sequence in the catalytic domain could account for the dierences in protein kinase activity that we had previously observed. We therefore assayed the cell extracts described above for the activation of DRaf:ER proteins and for MEK and p42 MAP kinase activities using the appropriate assays as described previously and in Materials and methods Samuels et al., 1993) . Since the experiments were conducted in parallel and equivalent exposures of the autoradiographs and Western blots are presented, it is reasonable to compare the kinase assays in ®gure 4, panels a-c, panels d-f and panels g-i to one another respectively.
Activation Oncogenic transformation of Rat1 cells by DRaf:ER proteins. Rat1 cells were infected with replication-defective retrovirus stocks derived from the dierent pBP3DRaf:ER plasmids described above and infected cells were selected by culture in DMEM containing puromycin. Pools of 510 5 puromycin resistant colonies expressing the dierent DRaf:ER proteins were trypsinized and established in culture. These cells were grown until they were approximately 80% con¯uent at which time they were either treated with 0.1% (v/v) ethanol (7ICI Panel A, C, E, G, I, K, M, O and Q) or with 1 mM ICI 182,780 (+ICI, Panels B, D, F, H, J, L, N, P, R) to activate the DRaf:ER proteins. Cells were cultured for a futher 48 h at which point they were photographed using a Nikon TMS micrscope at 1206 magni®cation. DA-Raf [YY] :ER (A and B), DA-Raf [FF] :ER (C and D), DA-Raf [DD} :ER (E and F), DB-Raf [YY] :ER (G and H), DB-Raf [FF] :ER (I and J), DB-Raf [DD] :ER (K and L), DRaf-1 [YY] :ER (M and N), DRaf-1 [FF] :ER (O and P) and DRaf-1 [DD] :ER (Q and R) Raf:ER gave rise to similar levels of MEK and p42 MAP kinase activity whereas the [FF] form gave rise to a slightly lower fold activation of both of these enzymes ( Figure 4f and i, respectively).
Activation of all three forms of DRaf-1:ER also led to activation of kinase activity towards GST-MEK1 however we detected signi®cant dierences in catalytic activity between the dierent forms of the protein (Figure 4a ). DRaf-1 [DD] :ER displayed a much greater kinase activity towards GST-MEK1 than the [FF] and [YY] forms of DRaf:1:ER. DRaf-1 [YY] :ER displayed a higher activity towards GST-MEK1 than DRaf-1 [FF] :ER in this experiment but this dierence was not reproducible. In general, the in vitro dierences in DRaf-1:ER catalytic activity were re¯ected in the relative abilities of these kinases to activate MEK and p42 MAP kinase in the cell with the [DD] form more potent than the [FF] or [YY] forms of DRaf-1:ER (Figure 4d and g, respectively). However, the magnitude of MEK and p42 MAPK activation by the dierent forms of DRaf-1:ER did not exactly mirror the dierences in Raf catalytic activity observed in vitro as will be discussed later.
A similar pattern of protein kinase activity was detected with the dierent forms of DA-Raf:ER (Figure 4b ). DA-Raf [DD] Figure  4e ). However, consistent with the transformation assays, activation of DA-Raf [YY] :ER gave rise to detectable p42 MAP kinase activation whereas DARaf [FF] :ER did not (Figure 4h ).
In order to conduct a side by side comparison of the level of p42 MAP kinase activity in cells transformed by the dierent DRaf:ER proteins, we prepared lysates of Rat1 cells in which the dierent DRaf:ER fusion proteins were fully activated after 48 h of treatment with 1 mM ICI. The catalytic activity of p42 MAP kinase was measured as described in Materials and methods. The highest level of p42 MAP kinase activity was detected in lysates from cells expressing DA-Raf [DD] :ER and the [YY] and [DD] forms of DB-Raf:ER and DRaf-1:ER ( Figure 5a , lanes 2, 4, 5, 7 and 8 respectively). Intermediate levels of p42 MAP kinase activation were detected in cells expressing the [FF] forms of DBRaf:ER and DRaf-1:ER and low level activation was observed in cells expressing DA-Raf [YY] :ER. The level of p42 MAP kinase activity in cells expressing DARaf [FF] :ER was similar to that seen in normal asynchronously growing Rat1 cells (data not shown) consistent with the inability of this protein to elicit oncogenic transformation in these cells. These data contrast with the in vitro catalytic activities of the dierent DRaf:ER proteins. The large apparent differences in DRaf:ER catalytic activity were not re¯ected by equivalently large dierences in p42 MAP kinase activity in the intact cell. For example DRaf-1 [DD] :ER was apparently ten times more active than Raf-1 [YY] :ER yet the dierence in MAP kinase activation was at most twofold. These observations suggest that the ability of oncogenic Raf kinases to activate the MAP kinase pathway in mammalian cells may not simply be a function of Raf catalytic activity as we have observed previously in other cell types (Samuels et al., 1993) . Con®rmation of the level of in vivo MAP kinase activity was sought by analysing the phosphorylation of the Ets-2 transcription factor on threonine residue 72 which we have established as a good candidate target for MAP kinase in intact 3T3 cells (McCarthy et al., 1997) . The level of T72 Ets-2 phosphorylation in cells transformed by the dierent DRaf:ER proteins mirrored the extent of p42 MAP kinase activation that we observed in the experiment described above (Ostrowski, unpublished observations).
Induction of HB-EGF gene expression by DRaf:ER activation
We have previously characterized the HB-EGF gene as an immediate-early transcriptional target of activated Ras and Raf oncogenes (McCarthy et al., 1995) . We have further demonstrated that activation of HB-EGF transcription in 3T3 cells is most likely initiated by et al., 1995) . Induction of HB-EGF mRNA expression was quantitated by taking the ratio of the HB-EGF speci®c band to the GAPDH speci®c band. In accord with the biochemical analysis of the MAP kinase cascade described above, activation of all three forms of DB-Raf:ER led to the induction of HB-EGF mRNA (Figure 6c 3) , DB-Raf:ER (lanes 4 ± 6) and DRaf-1:ER (lanes 7 ± 9) treated with ICI for 48 h was measured by an immunoprecipitation kinase assay using Myelin Basic Protein (MBP) as a substrate (a). After quantitation of MBP phosphorylation using a PhosphorImager the Western blot in a was reprobed with a monoclonal antibody that recognizes p42/p44 MAP kinase to allow estimation of the relative amount of p42 MAP kinase in each immunoprecipitate (b)
Comparison of relative catalytic activity of the DRaf:ER protein kinases expressed in Rat1 Cells
In order to make a direct comparison of the relative catalytic activity of the dierent DRaf:ER proteins we prepared cell extracts from Rat1 cells expressing the dierent DRaf:ER proteins that had been treated with 1 mM ICI for 48 h. Equal amounts of the dierent DRaf:ER proteins were immunoprecipitated using the anti-hbER antisera and were incubated in a kinase reaction in which the concentrations of substrate were approximately ten times higher than their published K m values (13 mM GST-MEK1 and 100 mM ATP respectively) (Force et al., 1994) . In accord with the results in Figure 4 all of the forms of DB-Raf:ER demonstrated potent catalytic activity towards GST-MEK1 ( Figure  7a , lanes 4 ± 6) indicating that the engineered mutations had no signi®cant eect of catalytic activity. (Figure 7a, lane 1) . Similarly, DA-Raf [FF] :ER, which is at best only very weakly transforming, displayed little or no detectable kinase activity towards GST-MEK1 (Figure 7a, lane 3) . By contrast, DA-Raf [DD] :ER was able to phosphorylate GST-MEK1 to the same eciency as the [YY] and [FF] forms of DRaf-1:ER (Figure 7a, lane 2) . Equal loading of the DRaf:ER proteins was con®rmed by probing the Western blot presented in Figure 7a with the antihbER antiserum (Figure 7c ). Reprobing of this Western blot with the 4G10 anti-phosphotyrosine monoclonal antibody revealed that none of the DRaf:ER proteins was detectably tyrosine phosphorylated.
Comparison of relative catalytic activity of DRaf:FH 6 protein kinases expressed in baculovirus infected Sf9 cells
In order to con®rm these results we expressed all nine of the DRaf proteins described above as FLAG-His 6 epitope-tagged proteins using a baculovirus transfer vector (pVL1393:FH 6 ) in Sf9 cells as described previously . In order to measure the kinase activities of these proteins we immunoprecipitated approximately equal amounts of DRaf:FH 6 with an anti-FLAG antibody (M2) coupled to agarose and measured catalytic activity using GST-MEK1 as a substrate. In good agreement with the results obtained with the DRaf:ER fusion proteins expressed in Rat1 cells, we found that all of the DBRaf:FH 6 displayed the highest level of kinase activity towards GST-MEK1 (Figure 7b , lanes 4 ± 6 as indicated). Under the conditions of this experiment we could detect no signi®cant dierence between the activities of the dierent forms of DB-Raf:FH 6 . In accord with the results of the DRaf:ER kinase assays we observed that DRaf-1 [DD] :FH 6 was approximately 10 times more active than DRaf-1 [YY] :FH 6 and DRaf-1 [FF] :FH 6 (Figure 7b , lanes 8, 7 and 9, respectively). Indeed the level of activity of DRaf-1 [DD] :FH 6 was similar to the level of activity displayed by all of the DB-Raf:FH 6 proteins. Finally, we found that DARaf [DD] :FH 6 phosphorylated GST-MEK1 as eciently as DRaf-1 [YY] :FH 6 (Figure 7b , lanes 2 and 7, respectively), but we remained unable to detect any dierence in the ability of the [YY] and [FF] forms of DA-Raf to phosphorylate GST-MEK1 (Figure 7b,  lanes 1 and 3, respectively) .
Overall, the relative kinase activities of the dierent DRaf:FH 6 proteins were similar to that observed with the dierent DRaf:ER proteins expressed in Rat1 cells. and e, c and f respectively) were either untreated or treated with 1 mM ICI for 4, 24 or 48 h as indicated at which times the cells were harvested and total RNA was isolated using the RNeasy protocol (Qiagen). RNase protection assays to simultaneously measure HB-EGF (a, b and c) and GAPDH as an internal reference (d, e and f) of the mRNA levels were carried out as described in Materials and methods Equal loading of the Western blot in panel b was con®rmed by probing with the M2 anti-FLAG monoclonal antibody. This also revealed that many of the DRaf:FH 6 proteins migrated as doublets consisting of a major band of faster mobility and a minor band of reduced mobility (Figure 7d ). These data suggested that a fraction of the DRaf:FH 6 proteins were phosphorylated when expressed in Sf9 cells. Indeed when this Western blot was reprobed with a monoclonal anti-phosphotyrosine antibody (4G10) we observed that a sub-population of the DB-Raf [YY] :FH 6 protein, but none of the others, was tyrosine phosphorylated (data not shown). In view of the lack of tyrosine phosphorylation of the dierent DRaf:ER proteins expressed in Rat1 cells and the elevated activity of the non-tyrosine phosphorylated DBRaf [FF] :FH 6 protein, it is unlikely that the tyrosine phosphorylation is having a signi®cant in¯uence on the interpretation of the relative kinase activities of the dierent DB-Raf kinases expressed in Sf9 cells.
DRaf
The results obtained in Rat1 and Sf9 cells expressing the dierent DB-Raf:ER and DB-Raf:FH 6 proteins suggested that DB-Raf catalytic function is largely unaected by mutation of the negatively charged aspartic acid residues found at positions 492 and 493 to either tyrosine or phenylalanine. This result contrasts with the observation that changing the tyrosine residues found at the analogous positions of DA-Raf and DRaf-1 increased catalytic activity approximately tenfold. In order to determine if the changes in amino acid sequence of DB-Raf had an eect of the kinetics of protein kinase activity we measured GST-MEK1 phosphorylation by the dierent forms of DB-Raf:FH 6 as a function of time under conditions where the substrates were in excess. Consistent with the data in Figure 7 we found that the initial rate of GST-MEK1 phosphorylation by the dierent forms of DB-Raf:FH 6 was almost identical (data not shown).
Discussion
The mechanisms of regulation of the Raf family of protein kinases have been the subject of considerable interest. Current models hold that the activation of Raf-1 in response to growth factors such as EGF is initiated by the Ras-mediated recruitment of Raf-1 to the plasma membrane where it is activated by a mechanism that most likely involves tyrosine phosphorylation by members of the Src family of protein tyrosine kinases (Fabian et al., 1993; Marais et al., 1995) .
Support for a regulatory role of tyrosine phosphorylation has come from evidence that Raf-1 is tyrosine phosphorylated in response to ligand stimulation 3) , DB-Raf:ER (lanes 4 ± 6) and DRaf-1:ER (lanes 7 ± 9) in extracts of Rat1 cells treated with ICI for 48 h was measured by an immunoprecipitation kinase assay using GST-MEK1 as a substrate (a). After quantitation of GST-MEK1 phosphorylation using a PhosphorImager the Western blot in a was reprobed with a polyclonal anti-ER antibody that recognizes all of the DRaf:ER proteins to allow estimation of the relative amount of DRaf:ER proteins in each immunoprecipitate (c). DNA sequences encoding all of the DRaf protein kinases were subcloned into pVL1393:FH 6 such that they were tagged at the carboxy-terminus with the FLAG epitope followed by six consecutive histidine residues. The catalytic activity of the [YY] , [DD] and [FF] forms of DA-Raf:FH 6 (Lanes 1 ± 3), DB-Raf:FH 6 (lanes 4 ± 6) and DRaf-1:FH 6 (lanes 7 ± 9) was measured by an immunoprecipitation kinase assay using GST-MEK1 as a substrate (b) After quantitation of GST-MEK1 phosphorylation using a PhosphorImager the Western blot in b was reprobed with the M2 monoclonal antibody that recognizes the FLAG epitope to allow estimation of the relative amount of DRaf:FH 6 proteins in each immunoprecipitate (d).
particularly in cells of hematopoietic origin (Carroll et al., 1991; Turner et al., 1991) , in cells transformed by oncogenic Ras (Jelinek et al., 1996) and in cells exposed to ionizing radiation (Kasid et al., 1996) . Furthermore, experiments in both mammalian and Sf9 cells have implicated two adjacent tyrosine residues in the catalytic domain of Raf-1 (Y340 and Y341) as being important for the regulation of Raf-1 kinase activity. Indeed it has been shown that the conversion of either one of these two tyrosine residues to aspartic acid is sucient to activate the oncogenic potential of full length p74 Raf-1 (Fabian et al., 1993) . It is assumed that the substitution of negatively charged aspartic acid residues into these sites mimics, at least in part, the eects of tyrosine phosphorylation of the protein at these sites. Similarities of sequence suggest that A-Raf may be regulated in a manner analogous to Raf-1 however, the catalytic domain of B-Raf encodes aspartic acid residues in the analogous positions suggesting that the regulation of B-Raf may diverge from that of the other family members.
We have previously demonstrated dierences in activity between the dierent Raf kinases when expressed in mammalian or insect cells. Catalytic activity of the dierent Rafs correlated with the ability of the proteins to both activate MEK and oncogenically transform NIH3T3 cells. Interestingly the mitogenic properties of the dierent Raf kinases appeared to show an inverse correlation with catalytic activity as DA-Raf:ER elicited a stronger mitogenic response in quiescent 3T3 cells than DB-Raf:ER and DRaf-1:ER . It appears that 3T3 cell proliferation is promoted by a low level of Raf activity whereas high level Raf activity elicits cell cycle arrest (Woods et al., manuscript submitted).
Given the dierences in sequence between the Raf catalytic domains and the potential importance of these dierences in determining catalytic activity we have analysed the eects of expressing mutant forms DBRaf, DA-Raf and DRaf-1 encoding either aspartic acid, tyrosine or phenylalanine at the aforementioned positions. We found that mutation of these tyrosine residues to aspartic acid signi®cantly increased the activity of DRaf-1 and DA-Raf. These data support previous work that demonstrated that negative charges at these positions in Raf-1 increased catalytic activity and lends support for a role for tyrosine phosphorylation in the regulation of Raf-1 and A-Raf kinase activity. In contrast, DB-Raf catalytic activity was not changed signi®cantly by mutating the analogous aspartic acid residues to either tyrosine or phenylalanine. Consequently, these aspartic acids residues do not fully account for the higher catalytic activity exhibited by DB-Raf.
An interesting result to emerge from this study was the apparent inability of the [FF] form of DA-Raf:ER to transform Rat1 and NIH3T3 cells whereas the [FF] forms of DRaf-1:ER and DB-Raf:ER were ecient oncogenes. These data indicate that the presence of hydroxyl groups or a negative charge at these positions in DA-Raf is essential for the protein to be active in the cells currently under analysis. Interestingly the DARaf [FF] :ER protein may not be completely biologically inactive as it is able to convert FDC-P1 cells to an IL-3 independent phenotype at a low frequency (Hoyle et al., unpublished observations).
Despite the fact that DA-Raf interacts with MEK1 in the two-hybrid system in S. Cerevisiae we have been unable to show that DA-Raf [YY] is able to phosphorylate and activate MEK1 in vitro (Bosch and McMahon, unpublished observations; Pritchard et al., 1995) . Others have however reported that immunoprecipitates of full length p68
A-Raf from primary cardiac myocytes stimulated with endothelin 1 (ET1) or TPA, or from Hela cells stimulated with EGF were capable of phosphorylating MEK in vitro (Bogoyevitch et al., 1995; Wu et al., 1996) . The results presented here may therefore help to resolve this apparent discrepancy since the [DD] form of DA-Raf eciently phosphorylated MEK in vitro. Since the extent of tyrosine phosphorylation of p68
A-Raf was not assessed in the aforementioned studies it is possible that the eects of the [DD] mutation reveal that the catalytic activity of A-Raf has a strong requirement for negative charges in these sites. It is also possible that phosphorylation of A-Raf on other residues may also increase its kinase activity toward MEK1.
We had anticipated that changing the analogous aspartic acid residues in DB-Raf would reduce the catalytic activity of the protein to that seen with DRaf-1 [YY] . By contrast all of the forms of DB-Raf:ER/DBRaf:FH 6 were highly active and not signi®cantly altered by mutation of these amino acids. These data indicate that the simple model that suggests that the increased catalytic activity of B-Raf is a consequence of a minor dierence in the sequence of the catalytic domain is largely incorrect. The fact that the catalytic activity of DB-Raf was independent of negative charge in these residues, suggest that the higher intrinsic catalytic activity of B-Raf depends on other characteristics of the molecule. Experiments are under way to address this possibility.
Although none of the DRaf:ER proteins expressed in mammalian cells was detectably tyrosine phosphorylated we found that a sub-population of the DBRaf [YY] :FH 6 protein expressed in Sf9 cells was tyrosine phosphorylated. Since neither the [DD] nor the [FF] forms of DB-Raf:FH 6 were tyrosine phosphorylated it seems likely that the site(s) of phosphorylation are those that we have generated by mutation. By contrast the [YY] forms of DRaf-1 or DA-Raf were not detectably tyrosine phosphorylated indicating a speci®city for the DB-Raf [YY] :FH 6 protein. These results suggest that DB-Raf [YY] :FH 6 is being phosphorylated by a protein tyrosine kinase that is intrinsic to Sf9 cells. To date only one Raf homologue has been identi®ed in the simple eukaryotes D. melanogaster and C. elegans. These Raf homologues have been described to be most like mammalian B-Raf and consistent with this hypothesis both genes encode aspartic acid residues in the sites analogous to those under study in this report (Han et al., 1993; Mark et al., 1987) . The presence in Sf9 cells of a protein tyrosine kinase that speci®cally phosphorylates mutated mammalian DB-Raf [YY] may either be a fortuitous observation or an indication that the Spodoptera frugiperda Raf homologue may encode tyrosine(s) in the aforementioned sites or may be an indicator that there are additional Raf homologues yet to be discovered in insect cells.
All of the transforming DRaf:ER proteins were able to activate the expression of the previously identi®ed immediate-early Raf target gene, HB-EGF (McCarthy et al., 1995) . In accord with the transformation data, the [DD] forms of DRaf:ER activated the expression of the gene to the greatest extent but the fold induction of HB-EGF did not necessarily match with the fold dierences in catalytic activity between the dierent DRaf:ER proteins. For example, despite the dierences in catalytic acitvity between the [YY] and [DD] forms of DRaf-1:ER the kinetics and extent of HB-EGF activation were similar. These data suggest that there is a rate-limiting step in the activation of gene transcription that occurs downstream of the activation of the DRaf:ER proteins. This idea is supported by the observation that DRaf-1 [DD] :ER is approximately ten times more active than DRaf-1 [YY] :ER but their relative abilities to activate p42 MAP kinases are only 2 ± 3-fold dierent. Indeed we have previously demonstrated that other factors such as the activity of cellular phosphoprotein phosphatases can play a role in determining the outcome of signaling through the Raf pathway such that activation of DRaf-1:ER in Rat1a cells leads to MEK activation in the absence of detectable MAP kinase activation (Samuels et al., 1993) . It is therefore possible that such molecules are having an in¯uence on MAP kinase activation under the circumstances described here. It is also worthy of note that we are analysing the activity of constitutively activated forms of the Raf kinases whereas the Raf proteins are normally activated transiently in response to the engagement of plasma membrane receptors. It is possible that the relevant dierences in Raf catalytic activity may be more signi®cant in determining the extent of activation of signaling pathways contolled by Raf kinases in response to physiological concentrations of exogenous growth factors.
At present it is not clear what the consequences of tyrosine phosphorylation (or aspartic acid substitution) have on the dierent parameters of catalytic activity. In addition to increasing the catalytic activity of the isolated kinase domain it is possible that tyrosine phosphorylation of Raf-1 may play a role in relieving the inhibitory eects of the CR2 region of the protein (not contained within the portion of the three Rafs under investigation here). Given the importance of tyrosine phosphorylation in mediating protein-protein interactions it is also possible that such modi®cations could target Raf for interactions with other cellular proteins such as has been reported with Lck and Fyn (Clark et al., 1994; Iwashima et al., 1994) . In the context of the isolated Raf kinase domains, tyrosine phosphorylation could aect the K m and/or the V max of the enzyme. We are presently using standard enzyme kinetic measurements and the BIAcore to measure these eects.
In conclusion, we propose that these data support the hypothesis that suggests that the dierent Raf kinases may be dierentially coupled to upstream signaling pathways. Consistent with a variety of in vitro studies, B-Raf activation may only require binding to Ras.GTP (Moodie et al., 1994; Tamamori et al., 1995) . Although there is no evidence that Rasmediated activation of Raf-1 has an absolute requirement for tyrosine phosphorylation the results reported here are consistent with a role for tyrosine phosphorylation being able to strongly potentiate Raf-1 catalytic activity. Finally activation of A-Raf may have strong dependency on both Ras activation and tyrosine phosphorylation.
Materials and methods
Construction of Raf mutants
Site directed mutagenesis was used to mutate tyrosine residues 299 and 300 in the catalytic domain of mouse ARaf to either aspartic acid or phenylalanine and aspartic acid residues 492 and 493 in mouse B-Raf to either tyrosine or phenylalanine (Deng & Nickolo, 1992) . The primers used to construct these mutations were as follows: A-Raf (Y299D,Y300D): 5'-CCGGGACTCAGGCGATGACTGG-GAGGTGC-3', A-Raf (Y299F,Y300F): 5'-CCGGGACTC-AGGCTTTTTCTGGGAGGTGC -3; B -Raf (D49 -2Y, D493Y); 5'-GGTAGAAGAGATTAAGTTATTACTGGG-AGATTCCTGATG-3', B-Raf (Y492F,Y493F): 5'-GGTA-GAAGAGATTCAAGTTTTTTCTGGGAGATTCCTGAT-GG-3'.
To improve the frequency of recovering mutants we simultaneously replaced an XmnI site in pGEM7:DA-Raf, and AlwNI site pGEM7:DB-Raf with the unique restriction sites EcoRV and SpeI, respectively using the following selection primers: A-Raf trans-oligo XmnI/EcoRV, 5'-GCTCAT-CATTGGATATCGTTCTTCGGG-3'; B-Raf trans-oligo AlwN I/SpeI, 5'-GCAGCCACTAGTAACAGGATT-3'; BRaf switch-oligo SpeI/AlwN I 5'-GCAGCCACTGGTAA-CAGGATT-3' (Clontech). The selection trans-oligo XmnI/ EcoRV together with the appropriate mutagenic A-Raf primers were used to create pGEM7:DA-Raf [DD] and pGEM7:DARaf [FF] . The selection trans-oligo AlwNI/SpeI together with the appropriate B-Raf mutagenic primer was used to create pGEM7:DB-Raf [YY] . Having isolated pGEM7:DB-Raf [YY] , it was used as a template for the selection switch-oligo SpeI/ AlwnI and the appropriate B-Raf mutagenic primer to create pGEM7:DB-Raf [FF] .
Mutants of human Raf-1 [Y340D,Y341D] and [Y340F,Y34F] were very kindly provided by Dr Deborah Morrison (NCI, Frederick, Maryland) . P¯MI ± BgIII fragments of Raf-1 that included the mutated codons were subcloned into pBS:DRaf-1, encoding the kinase domain of human Raf-1 as reported previously, to generate pBS:DRaf-1 [DD] and pBS:DRaf-1 [FF] (Samuels et al., 1993) . XhoI ± EcoRI fragments encoding the dierent forms of the kinase domains of Raf-1, A-Raf and B-Raf we subcloned into pBP3:hbER, a replication-defective murine retrovirus vector derived from pBabePuro (Morgenstern and Land, 1990 ) that encodes the hormone binding domain of the HE14 allele of the human estrogen receptor (hbER) (Figure 1 ). This created in-frame fusions between sequences encoding the [YY], [DD] and [FF] forms of DRaf-1, DA-Raf and DB-Raf and hbER as has been described previously Samuels et al., 1993) . We thus generated retrovirus vectors (pBP3DRaf:ER) encoding DRaf-1 [YY] :ER, DRaf-1 [DD] :ER, DRaf-1 [FF] :ER, DARaf [YY] :ER, DA-Raf [DD] :ER, DA-Raf [FF] :ER, DB-Raf [YY] :ER, DB-Raf [DD] :ER and DB-Raf [FF] :ER as depicted in Figure 1 .
Expression of epitope-tagged DRaf:FH 6 kinases in Sf9 cells
The dierent DRaf mutants were subcloned into a baculovirus transfer vector as described previously . NcoI ± EcoRI fragments encoding the kinase domains of the dierent forms of Raf-1, A-Raf and B-Raf were cloned into pVL1393:FH 6 to generate pVLDRaf-1 [YY] :FH 6 , pVLDRaf-1 [DD] :FH 6 , pVLDRaf-1 [FF] : FH 6 , pVLDA-Raf [YY] :FH 6 , pVLDA-Raf [DD] :FH 6 , pVLDARaf [FF] :FH 6 , pVLDB-Raf [YY] :FH 6 , pVLDB-Raf [DD] :FH 6 and pVLDA-Raf [FF] :FH 6 respectively. This cloning vector is a modi®ed form of pVL1393 into which sequences encoding the FLAG epitope (DYKDDDK, Kodak/IBI) followed by six consecutive histidine residues had been inserted. The insertion of the DRaf kinase domains into this vector leads to the expression of epitope-tagged forms of the proteins in Sf9 cells (Figure 1 Cell culture, retrovirus production, and infection All cells were cultured in Phenol Red free Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum (FCS), penicillin and streptomycin at 378C in a humidi®ed atmosphere containing 6% (v/v) CO 2 . Cells were photographed with a Nikon TMS photomiscroscope. ICI 182,780 (hereafter referred to as ICI), an estrogen receptor antagonist, was provided by Dr Alan Wakeling (Zeneca Pharmaceuticals, Maccles®eld, UK) and was prepared as a 1 mM stock in ethanol and stored at 7208C. Virus stocks encoding the DRaf:ER alleles were obtained by Lipofectamine (Gibco-BRL) mediated transfection of the pBP3DRaf:ER vectors into Bosc23 cells (Pear et al., 1993) . Brie¯y 12.5 mg of supercoiled plasmid DNA was mixed with 90 ml of Lipofectamine in a total volume of 2 ml of OPTI-MEM-I (Gibco-BRL) medium. The DNA/ Lipofectamine mix was incubated for 6 h with 5610 6 Bosc23 cells that had been plated onto a 10 cm dish 12 h previously. After this incubation 10 ml of OPTI-MEM-I media containing 20% FCS was added and the incubation continued for a further 19 h. Virus stocks were harvested over the following 24 h into 5 ml of Phenol Red free DMEM containing 10% (vv) FCS and then used to infect Rat1 and 3T3 cells. Forty-eight hours following infection, the cells were trypsinized and placed in medium containing 2 mg/ml puromycin (Sigma) to select for virus-infected cells. Standard virus stocks gave rise to 510 6 puromycin resistant colonies per ml of virus. Following selection in puromycin, cells were pooled, expanded and tested for the expression of DRaf:ER proteins by Western blotting. Under these conditions 595% of the puromycin resistant Rat1 or 3T3 colonies express the DRaf:ER fusion proteins (Cherwinski and McMahon, unpublished observations).
Assessment of DRaf:ER-induced oncogenic transformation
To test for DRaf:ER induced morphological transformation, the pooled populations described above were plated and grown in DMEM containing 10% FCS until they were approximately 80% con¯uent. At this time the cells were treated with either 0.1% (v/v) ethanol as a solvent control or with either 1 mM b-estradiol, 4-Hydroxy-Tamoxifen or ICI 182,780, and the cells were monitored over the following 72 h. All of these compounds have been shown to elicit the biochemical and biological activation of DRaf-1:ER (Samuels et al., 1993) . The ability of the dierent DRaf:ER proteins to elicit morphological transformation was also assessed in Rat1 cells that were grown to 80% con¯uency in DMEM containing 10% FCS and then switched to DMEM containing 1% (w/v) BSA with no FCS prior to the addition of hormones with identical results.
Preparation of cells extracts and analysis by Western blot
Triton X-100-soluble cell lysates were prepared as described previously (Samuels et al., 1993) . Cells were lysed in Gold lysis buer (GLB), and protein concentrations were measured using the BCA protein assay kit (Pierce). Aliquots of cell lysates were electrophoresed through polyacrylamide gels and Western blotted onto Immobilon P polyvinylidene di¯uoride membranes (Millipore). Western blots were probed with 1:2500 dilutions of either an antihbER polyclonal antiserum (HC-20) (Santa Cruz Biotechnology), an anti-FLAG monoclonal antibody (M2) (Kodak/ IBI), or an anti-phosphotyrosine monoclonal antibody (4G10, UBI) for at least 1 h. The ®lters were washed in Tris-buered saline containing 0.5% (v/v) Nonidet P-40 and incubated with the appropriate secondary antibody coupled to horseradish peroxidase (hrp). The enhanced chemiluminescence detection system (Amersham) was utilized to visualize the antigen-antibody complexes.
Assay for Raf kinase activity
Immune-complexes of DRaf:ER or DRaf:FH 6 were prepared by incubating cell lysates with either the anti-hbER and protein A-Sepharose 4B (Pharmacia) or M2-agarose anti-FLAG antisera (Kodak/IBI). Immune-complexes were collected, washed in lysis buer and the activities of DRaf:ER and DRaf:FH 6 were assessed by incubation for 30 min at 308C in a reaction mix containing 25 mM HEPES (pH 7.4), 10 mM MgC1 2 , 1 mM MnC1 2 , 1 mM DTT, 50 mM ± 100 mM ATP and 10 mCi of [g-32 P]ATP (Amersham) with 3 ± 15 mg (2.6±13 mM) of puri®ed recombinant enzymatically inactive GST-MEK1[K97R] as a substrate. The reactions were analyzed by polyacrylamide gel electrophoresis and Western blotting. Western blots were ®rst quantitated using a Molecular Dynamics PhosphorImager to measure GST-MEK1[K97R] phosphorylation and subsequently probed with either the anti-hbER or the anti-FLAG antisera as appropriate to quantitate the amounts of the DRaf kinases in each immunoprecipitate.
Assay for MEK activity
Aliquots from unfractionated cell lysates containing 60 mg of total protein were incubated for 30 min at 308C in a reaction mix containing 40 mM HEPES pH 7.8, 10 mM MgCl 2 1 mM DTT and 40 ml ATP and 2 mg of bacterially expressed rp42, which is an enzymatically inactive form of p42 MAP kinase. The reaction mixtures were electrophoresed through a 10% polyacrylamide gel, which was then Western blotted and exposed to X-ray ®lm. Tyrosine phosphorylation of rp42 was quantitated by probing the Western blot with 4G10-hrp, a horseradish peroxidaseconjugated anti-phosphotyrosine monoclonal antibody.
Assay for p42 kinase activity
Sixty mg of cell extract was incubated for 2 h at 48C with 5 ml of an anti-p42 MAP kinase polyclonal antiserum conjugated to agarose beads. Immune-complexes were collected and washed twice with lysis buer and once with a buer containing 25 mM Tris (pH 7.5), 137 mM MgC1 2 and 10% (v/v) glycerol. Immune-complexes were incubated for 30 min at 308C in a reaction mix containing 40 mM HEPES pH 7.4 40 mM MgC1 2 , 200 mM ATP, and 5 mCi of [g-32 P]ATP with 20 mg of Myelin Basic Protein (MBP) as a substrate. The reactions were analysed and quantitated on SDS polyacrylamide gels as described above. Western blots were ®rst quantitated using a Molecular Dynamics PhohphorImager to measure MBP phosphorylation and subsequently probed with anti-p42 MAP kinase to quantitate the amounts of the MAP kinases in each immunoprecipitate.
Ribonuclease protection assays
Rat1 cells expressing the dierent DRaf:ER proteins grown to 80% con¯uency on 15 cm cell culture plates were either untreated or treated with 1 mM ICI for 4, 24 or 48 h at which time total cellular RNA was isolated using the RNeasy kit (Qiagen) according to the manufacturer's instructions and as described previously (McCarthy et al., 1995) . Simultaneous quantitation of the level of expression of HB-EGF and GAPDH mRNAs was conducted using a Ribonuclease protection assay as described previsouly (McCarthy and Bicknell, 1992; McCarthy et al., 1995) .
